The ACER1 Knockout MCF-7 Polyclonal Cells product consists of a heterogeneous population of MCF-7 cells that have undergone CRISPR/Cas9-mediated disruption of the ACER1 gene, which encodes alkaline ceramidase 1. This polyclonal knockout pool provides a versatile loss-of-function resource for elucidating the role of ceramide hydrolysis in sphingolipid signaling within a well-defined breast cancer context. As a genetically diverse population, it enables functional studies without the biases introduced by single-cell cloning, making it suitable for assays that require representative cellular responses.
The MCF-7 host cell line is a widely utilized model of estrogen receptor-positive (ER+) breast adenocarcinoma, originally established from the pleural effusion of a patient with metastatic mammary carcinoma. These cells retain expression of both estrogen receptor ?? and progesterone receptor, classifying them as luminal A subtype, and they are routinely employed for investigations into hormone-dependent proliferation, endocrine therapy resistance, and estrogen-regulated gene networks. Their well-characterized signaling landscape provides a robust backdrop for knockout-based pathway analysis.
ACER1 encodes an endoplasmic reticulum-resident alkaline ceramidase that hydrolyzes ceramides into sphingosine and free fatty acid, thereby diminishing pro-apoptotic ceramide pools and promoting the generation of sphingosine-1-phosphate (S1P). This enzymatic activity is regulated by upstream cues including calcium-induced keratinocyte differentiation, PPAR??/?? signaling, and glucocorticoid receptor pathways. Within the sphingolipid metabolic network, ACER1 interacts with ceramide synthases, sphingomyelinases, other ceramidases (ACER2, ACER3), sphingosine kinases, and S1P phosphatases to govern ceramide?CS1P rheostat dynamics. Downstream consequences include modulation of apoptosis markers such as cleaved caspase-3 and PARP, autophagy flux, and, in epidermal tissues, formation of cornified envelopes.
In the MCF-7 context, ACER1 knockout allows dissection of how altered ceramide metabolism intersects with estrogen receptor signaling to influence cancer cell fate. Given that ceramides can sensitize cells to apoptosis and that S1P promotes proliferation, loss of ACER1 is expected to shift the balance toward ceramide accumulation, potentially enhancing cell death susceptibility or altering hormone responsiveness. This model thus facilitates exploration of sphingolipid-mediated mechanisms in luminal A breast cancer, including interactions with endocrine therapies and pro-apoptotic agents.
This polyclonal knockout product is suited for a wide range of research applications, including ceramide quantification via LC-MS/MS, Western blot analysis of apoptosis proteins, S1P ELISA, RT-qPCR profiling of ceramide-metabolizing enzyme expression, flow cytometric assessment of cell cycle and apoptosis, MTT-based proliferation assays, and estrogen stimulation experiments. Lipidomics profiling and drug sensitivity studies focusing on ceramide-modulating compounds further expand its utility. For additional technical information or custom service requests, please contact Ascent Research.
